Search

Your search keyword '"Fradet, Y"' showing total 725 results
Start Over Author "Fradet, Y"
725 results on '"Fradet, Y"'

101. POD-07.09: Incidental Adenocarcinoma of the Prostate Discovered at the Time of Radical Cystectomy: Analysis of the Canadian Bladder Cancer Network Database

Author

Chalasani, V., primary, Martinez, C., additional, Izawa, J., additional, Aprikian, A., additional, Fradet, Y., additional, Estey, E., additional, Fairey, A., additional, Rendon, R., additional, Cagiannos, I., additional, Lacombe, L., additional, Lattouf, J., additional, Bell, D., additional, Drachenberg, D., additional, Kassouf, W., additional, and Chin, J., additional

Published
2009
Full Text
View/download PDF

102. MP-13.10: Achieving Pt0n0 at Radical Cystectomy: Outcomes of 135 Pt0n0 Bladder Cancer Patients Treated with Radical Cystectomy: The Canadian Bladder Cancer Network Experience

Author

Drachenberg, D., primary, Aprikian, A., additional, Chin, J., additional, Fradet, Y., additional, Izawa, J., additional, Estey, E., additional, Fairey, A., additional, Rendon, R., additional, Cagiannos, I., additional, Lacombe, L., additional, Lattouf, J., additional, Bell, D., additional, and Kassouf, W., additional

Published
2009
Full Text
View/download PDF

103. POD-07.10: Outcome Analysis of Bladder Cancer Patients Treated with Radical Cystectomy in a Universal Health Care System: A Multicenter Canadian Series of 2,287 Patients

Author

Yafi, F., primary, Aprikian, A., additional, Chin, J., additional, Fradet, Y., additional, Izawa, J., additional, Estey, E., additional, Fairey, A., additional, Rendon, R., additional, Cagiannos, I., additional, Lacombe, L., additional, Lattouf, J., additional, Bell, D., additional, Drachenberg, D., additional, and Kassouf, W., additional

Published
2009
Full Text
View/download PDF

109. 542 IMPROVED PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED BLADDER CANCER USING A PANEL OF FOUR CELL CYCLE REGULATORS

Author

Shariat, S.F., primary, Bolenz, C., additional, Karakiewicz, P.I., additional, Fradet, Y., additional, Bastian, P.J., additional, Ashfaq, R., additional, Groshen, S., additional, Nielsen, M.E., additional, Rigaud, J., additional, Mueller, S.C., additional, Heukamp, L.C., additional, Netto, G., additional, Lerner, S.P., additional, Sagalowsky, A., additional, Cote, R.J., additional, and Lotan, Y., additional

Published
2009
Full Text
View/download PDF

110. Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer

Author

Margulis, V., primary, Lotan, Y., additional, Karakiewicz, P. I., additional, Fradet, Y., additional, Ashfaq, R., additional, Capitanio, U., additional, Montorsi, F., additional, Bastian, P. J., additional, Nielsen, M. E., additional, Muller, S. C., additional, Rigaud, J., additional, Heukamp, L. C., additional, Netto, G., additional, Lerner, S. P., additional, Sagalowsky, A. I., additional, and Shariat, S. F., additional

Published
2009
Full Text
View/download PDF

111. POD-7.09: Combination of Cell Cycle Regulating Bio-markers Improves Prognosis in Patients with Organ Confined Urothelial Cancer at Radical Cystectomy

Author

Sagalowsky, A., primary, Shariat, S., additional, Karakiewicz, P., additional, Fradet, Y., additional, Ashfaq, R., additional, Stein, J., additional, Bastian, P., additional, Nielsen, M., additional, Suardi, N., additional, Montorsi, F., additional, Groshen, S., additional, Mueller, S., additional, Rigaud, J., additional, Heukamp, L., additional, Netto, G., additional, Lerner, S., additional, Cote, R., additional, and Lotan, Y., additional

Published
2008
Full Text
View/download PDF

114. MULTI-INSTITUTIONAL EVALUATION OF THE PREDICTIVE VALUE OF P53 IMMUNOHISTOCHEMICAL STAINING IN PATIENTS WITH PT1-2 N0 DISEASE AT RADICAL CYSTECTOMY

Author

Shariat, S., primary, Lotan, Y., additional, Karakiewicz, P., additional, Fradet, Y., additional, Ashfaq, R., additional, Stein, J., additional, Bastian, P., additional, Larue, H., additional, Nielsen, M., additional, Suardi, N., additional, Montorsi, F., additional, Groshen, S., additional, Müller, S., additional, Palapattu, G., additional, Karam, J., additional, Heukamp, L., additional, Netto, G., additional, Lerner, S., additional, Sagalowsky, A., additional, and Cote, R., additional

Published
2008
Full Text
View/download PDF

121. PD-11.02

Author

Lacombe, L., primary, Decobert, M., additional, Harel, F., additional, Larue, H., additional, Steinhoff, G., additional, Kinahan, J., additional, and Fradet, Y., additional

Published
2006
Full Text
View/download PDF

128. Urologic Paraneoplastic Syndromes.

Author

Hohenfellner, Markus, Santucci, Richard A., Tiguert, R., and Fradet, Y.

Abstract

Paraneoplastic syndromes represent a constellation of complex signs and symptoms that result from the release of various tumor-associated proteins rather than as a consequence of local or distant metastasis. Paraneoplastic syndromes have been estimated to occur in 15%-20% of all cancer patients. The syndromes may affect any of the systems of the body, may precede or follow the diagnosis of the underlying neoplasm, and may or may not parallel the course of the neoplasm in severity. The diagnosis and therapy for these syndromes can be challenging to a physician, but successful therapy may bring about worthwhile relief for the patient. These syndromes are important for many reasons. They occasionally aid in the early diagnosis of neoplasms, and they have aided in the discovery that many (and perhaps most) neoplasms produce hormones or other substances that can be used as tumor markers. These markers are of increasing use in early diagnosis, in following the course of neoplasm and targeting therapy. A better understanding of the precise mechanisms involved in neoplasm production of these remote effectsmay help to achieve a better understanding of the nature of the neoplastic process itself. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

132. In Reply: Re

Author

Goldenberg, S.L., primary, Klotz, L.H., additional, Srigley, J., additional, Jewett, M.A.S., additional, Mador, D., additional, Fradet, Y., additional, Barkin, J., additional, Chin, J., additional, Paquin, J.-M., additional, Bullock, M.J., additional, and LaPlante, S., additional

Published
1997
Full Text
View/download PDF

133. In Reply

Author

Goldenberg, S. L., primary, Klotz, L. H., additional, Srigley, J., additional, Jewett, M. A. S., additional, Mador, D., additional, Fradet, Y., additional, Barkin, J., additional, Chin, J., additional, Paquin, J.-M., additional, Bullock, M. J., additional, and LaPlante, S., additional

Published
1997
Full Text
View/download PDF

136. Treatment with finasteride following radical prostatectomy for prostate cancer

Author

Andriole, G., primary, Lieber, M., additional, Smith, J., additional, Soloway, M., additional, Schroeder, F., additional, Kadmon, D., additional, Dekernion, J., additional, Rajfer, J., additional, Boake, R., additional, Crawford, D., additional, Ramsey, E., additional, Perreault, J., additional, Trachtenberg, J., additional, Fradet, Y., additional, Block, N., additional, Middleton, R., additional, Ng, J., additional, Ferguson, D., additional, and Gormley, G., additional

Published
1995
Full Text
View/download PDF

144. Symposium 23B: Molecular diagnosis of bladder cancer.

Author

Knowles, M.A., Têtu, B., Tiguert, R., Bernier, V., Couture, C., Fradet, Y., Stoehr, R., Knuechel, R., Hartmann, A., van Rhijn, B. W.G., van der Kwast, T.H., Vis, A.N., Kirkeis, W.J., Radvanyi, R., Chopin, D.K., and Zwarthoff, E.C.

Subjects
CANCER diagnosis, BLADDER cancer, CONFERENCES & conventions, TUMORS
Abstract

Reports on the topic related to molecular diagnosis of bladder cancer that was discussed during a symposium. Molecular changes in bladder carcinogenesis; Genetic alterations in flat urothelial neoplasia; Features of bladder cancer.

Published
2002
Full Text
View/download PDF

145. Lifetime occupational physical activity and incidental prostate cancer (Canada).

Author

Bairati, Isabelle, Larouche, René, Meyer, François, Moore, Lynne, Fradet, Yves, Bairati, I, Larouche, R, Meyer, F, Moore, L, and Fradet, Y

Subjects
COMPARATIVE studies, EXERCISE, RESEARCH methodology, MEDICAL cooperation, PROSTATE tumors, RESEARCH, TIME, OCCUPATIONAL hazards, ENVIRONMENTAL exposure, EVALUATION research, CASE-control method
Abstract

Objectives: The objective of this study was to assess the risk of incidental prostate cancer associated with occupational physical activity in a population of patients treated for benign prostatic hyperplasia (BPH) by transurethral resection of the prostate (TURP).Methods: This case-control study was conducted in men aged 45 and over referred for TURP to relieve the symptoms of BPH in one of the eight hospitals of the Quebec City area between October 1990 and December 1992. Cases (n = 64) were all men incidentally diagnosed with prostate cancer and controls were the 546 patients with solely a histological diagnosis of BPH. At the time of their interview, the patients completed a diet history questionnaire and a general questionnaire including a lifetime occupational history. Physical activity was estimated for each job according to data from the US Department of Labor. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) of incidental prostate cancer associated with occupational physical activity while adjusting for confounders.Results: A positive association was observed between "ever having a job with sedentary/light work" and incidental prostate cancer (OR = 1.9; 95% CI = 1.1-3.3). ORs for prostate cancer associated with 0%, 1-49%, and > or =50% of life spent in jobs with sedentary/light work were 1.0, 1.6 (95% CI = 0.8-3.1), and 2.5 (95% CI = 1.2-5.2), respectively (p-value for trend = 0.01). Occupational physical activity in the job held during the longest period was inversely associated with prostate cancer: ORs were 1.0, 0.5 (95% CI = 0.2-1.2), 0.4 (95% CI = 0.2-0.9) and 0.2 (95% CI = 0.1-0.7) for sedentary, light, moderate, and high/very high levels, respectively (p-value for trend = 0.008).Conclusions: The results of this study suggest that physical activity at work could have a beneficial effect on the occurrence of prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

146. Dietary fat and prostate cancer survival.

Author

Meyer, F, Bairati, I, Shadmani, R, Fradet, Y, and Moore, L

Abstract

Objectives: Relationships between dietary factors and the incidence of prostate cancer have emerged from epidemiologic and laboratory studies, but there are no published data on the relationship between diet and disease progression among prostate cancer patients. We studied the association between dietary fat intake and prostate cancer survival.Methods: We prospectively followed 384 men diagnosed with prostate cancer between 1990 and 1992 in the Quebec City area. On average 3 months following diagnosis, trained nutritionists interviewed the men on their usual diet using a diet history questionnaire. Deaths during follow-up were documented through record linkage with the provincial mortality file and review of hospital records. Cox proportional hazard models were used to estimate the relative risk of dying from prostate cancer associated with terciles of fat intake, expressed as percent of dietary energy, while controlling for prognostic factors and total energy.Results: The median duration of follow-up was 5.2 years. During the follow-up period 32 patients died of prostate cancer and 39 died of other causes. After controlling for grade, clinical stage, initial treatment, age and total energy intake, we found that saturated fat consumption was significantly associated with disease-specific survival (two-sided p-value = 0.008). Compared to men in the lower tercile of saturated fat, those in the upper tercile had three times the risk of dying from prostate cancer (relative risk = 3.1, 95% confidence interval: 1.3-7.7).Conclusions: Our findings suggest that saturated fat is related to disease-specific survival and that, if this relation is causal, a moderate reduction of its intake might reduce the risk of dying from prostate cancer. [ABSTRACT FROM AUTHOR]

Published
1999

149. Long-term Followup of a Randomized Trial of 0 Versus 3 Months of Neoadjuvant Androgen Ablation Before Radical Prostatectomy

Author

KLOTZ, L.H., GOLDENBERG, S.L., JEWETT, M.A.S., FRADET, Y., NAM, R., BARKIN, J., CHIN, J., and CHATTERJEE, S.

Abstract

In 1992 we initiated a national randomized prospective trial of 3 months of cyproterone acetate before radical prostatectomy compared to prostatectomy alone. Initial results indicated a 50% decrease in the rate of positive surgical margins. This decrease did not translate into a difference in prostate specific antigen (PSA) progression at 3 years. This report is on the long-term outcome (median followup 6 years) of this cohort.

Published
2003
Full Text
View/download PDF

150. Total Androgen Blockade for Metastatic Cancer of the Prostate

Author

John Trachtenberg, Fradet Y, Elhilali M, E W Ramsey, B Laroche, Gilles Béland, and P M Venner

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Neoplasms, Hormone-Dependent, medicine.drug_class, Imidazolidines, urologic and male genital diseases, Antiandrogen, Placebo, Buserelin, Placebos, Random Allocation, chemistry.chemical_compound, Double-Blind Method, Prostate, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Orchiectomy, Neoplasm Metastasis, business.industry, Remission Induction, Imidazoles, Prostatic Neoplasms, Cancer, Androgen Antagonists, Prognosis, medicine.disease, Combined Modality Therapy, Clinical trial, Castration, medicine.anatomical_structure, chemistry, business, Total Androgen Blockade
Abstract

This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.

Published
1988
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results